Document is current

Article History

Accepted: 19 May 2025

First Online: 27 June 2025

Declarations

:

: This study was funded by Amgen, Inc (formerly Horizon Therapeutics PLC).

: B. Freyne is a consultant to Amgen, Inc. (formerly Horizon Therapeutics). A. Kumar, Z. Vranic, and B. LaMoreaux are employees of and stockholders in Amgen, Inc. L. Padnick-Silver was an employee of and stockholder in Amgen, Inc at the time of the study.

: This was a retrospective deidentified medical record study reviewed and approved by the WIRB-Copernicus Group (WCG) international review board (IRB; Puyallup, WA). The study was assigned exempt status via WCG IRB, waiving the requirement of informed consent. The study does not include study-related procedures or examinations and was limited to the collection and analysis of deidentified standard-of-care data (including patient images) already present in the electronic medical record. The manuscript largely presents aggregate data of ten patients, and no individual patient identifying information is included. Hence, a consent to publish declaration was not applicable. All study conduct adhered to the tenets of the Declaration of Helsinki.

: Not applicable (details noted in Methods).

: Not applicable (details noted in Methods).

: Qualified researchers may request data from Amgen, with permission form United Rheumatology. Complete details are available at the following: .

: Not applicable.

: Conceptualization, B.F., L.P.S, A.K., and B.L.; formal analysis, Z.V., L.P.S., A.K., and B.L.; data curation, B.F.; writing—original draft preparation, Z.V.; writing—review and editing, B.F., Z.V., L.P.S., A.K., and B.L.; funding acquisition, B.L. All authors have read and agreed to the published version of the manuscript.